RVPH REVIVA PHARMACEUTICALS HLDGS INC

Reviva to Present at the UBS Virtual CNS Day

Reviva to Present at the UBS Virtual CNS Day

CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a Fireside Chat at the UBS Virtual CNS Day, taking place virtually March 18, 2024.

UBS Virtual CNS Day

    Format: Fireside Chat

    Date: Monday, March 18, 2024

    Time: 1:30 p.m. ET

    Location: Virtual

To register for the event, please or contact your UBS representative.

About Reviva 

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD 

Investor Relations Contact:

LifeSci Advisors, LLC

Bruce Mackle

Media Contact:

Kristin Politi



(646) 876-4783



EN
11/03/2024

Underlying

RVPHREVIVA PHARMACEUTICALS HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REVIVA PHARMACEUTICALS HLDGS INC

 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine ...

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present new pharmacology data on brilaroxazine as part of two poster presentation...

May 9, 2024 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for ND...

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Topline data from 1-year open-label extension (OLE) long-term safety trial expected in Q4 2024 - CUPERTINO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies tha...

April 15, 2024 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Reports Full Year 2023 Financial Results and Recent Business Hi...

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights – RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024; topline data expected Q2 2025 – – Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Most non-clinical activities completed and preparation is underway to support a New Drug Application (NDA) submission for brilaroxazin...

April 15, 2024 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazin...

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Researc...

March 28, 2024 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazin...

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the American Society for Clinical ...

March 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch